Journal
HEPATOLOGY
Volume 77, Issue 4, Pages 1287-1302Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.32631
Keywords
-
Categories
Ask authors/readers for more resources
Non-alcoholic fatty liver disease (NAFLD) affects nearly 25% of the global population and is associated with cardiovascular disease (CVD). A study found that apolipoprotein F (APOF) expression was negatively correlated with hepatic steatosis and plasma triglyceride (TG) levels in NAFLD patients. Further experiments showed that overexpression of APOF increased very low density lipoprotein (VLDL)-TG secretion and hepatic lipoprotein remnant clearance, leading to a reduction in plasma TG levels. These findings highlight the important role of APOF in plasma and hepatic lipoprotein metabolism.
Background: NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD, in line with highly prevalent dyslipidemia in this population. Increased plasma triglyceride (TG)-rich lipoprotein (TRL) concentrations, an important risk factor for CVD, are closely linked with hepatic TG content. Therefore, it is of great interest to identify regulatory mechanisms of hepatic TRL production and remnant uptake in the setting of hepatic steatosis. Approach and Results: To identify liver-regulated pathways linking intrahepatic and plasma TG metabolism, we performed transcriptomic analysis of liver biopsies from two independent cohorts of obese patients. Hepatic encoding apolipoprotein F (APOF) expression showed the fourth-strongest negatively correlation with hepatic steatosis and the strongest negative correlation with plasma TG levels. The effects of adenoviral-mediated human ApoF (hApoF) overexpression on plasma and hepatic TG were assessed in C57BL6/J mice. Surprisingly, hApoF overexpression increased both hepatic very low density lipoprotein (VLDL)-TG secretion and hepatic lipoprotein remnant clearance, associated a similar to 25% reduction in plasma TG levels. Conversely, reducing endogenous ApoF expression reduced VLDL secretion in vivo, and reduced hepatocyte VLDL uptake by similar to 15% in vitro. Transcriptomic analysis of APOF-overexpressing mouse livers revealed a gene signature related to enhanced ApoB-lipoprotein clearance, including increased expression of Ldlr and Lrp1, among others. Conclusion: These data reveal a previously undescribed role for ApoF in the control of plasma and hepatic lipoprotein metabolism by favoring VLDL-TG secretion and hepatic lipoprotein remnant particle clearance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available